Literature DB >> 7562478

Disposition of L-carnitine and acetyl-L-carnitine in the isolated perfused rat kidney.

A Mancinelli1, A Longo, K Shanahan, A M Evans.   

Abstract

The isolated perfused rat kidney was used to investigate the regulation, specificity and concentration-dependence of the renal tubular disposition of L-carnitine (LC) and its ester, acetyl-L-carnitine (ALC). Tritiated markers were used to study the renal disposition of LC and ALC and HPLC was used to purify 3H-LC and 3H-ALC before radiochemical analysis. At perfusate concentrations comparable to those found in plasma in vivo (50 microM for LC and 5 microM for ALC), the renal clearance of both analogues was substantially less than GFR (P < .05) which, in view of their negligible binding to perfusate proteins, is indicative of extensive reabsorption. During the first 20 min of perfusion, the percent tubular reabsorption (%TR) of LC and ALC was 94 +/- (SD) 2.6% and 97 +/- 0.6%, respectively. The extent of 3H-ALC and 3H-LC enrichment of perfusate in experiments with 3H-LC and 3H-ALC, respectively, provided evidence for the capability of the rat kidney to acetylate LC and deacetylate ALC. In addition, a portion of renally generated 3H-ALC and 3H-LC was found to undergo leakage into renal tubules and escape subsequent reabsorption. It was also found that the %TR of both compounds decreased substantially when the perfusate concentration was increased above endogenous levels; each compound was capable of decreasing the %TR of the other; and trimethylamine-N-oxide, a metabolite of LC, had no significant effect on the renal handling of the carnitine derivatives.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562478

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

Review 1.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

2.  Involvement of recognition and interaction of carnitine transporter in the decrease of L-carnitine concentration induced by pivalic acid and valproic acid.

Authors:  Noboru Okamura; Shuichi Ohnishi; Hiroyuki Shimaoka; Ryo Norikura; Hiroshi Hasegawa
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

3.  Progression of cyclophosphamide-induced acute renal metabolic damage in carnitine-depleted rat model.

Authors:  Mohamed M Sayed-Ahmed
Journal:  Clin Exp Nephrol       Date:  2010-07-23       Impact factor: 2.801

4.  Up-regulation of carnitine transporters helps maintain tissue carnitine levels in carnitine deficiency induced by pivalic acid.

Authors:  N Okudaira; M Fujigaki; T Nakayoshi; I Komiya; Y Sugiyama
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

5.  Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption.

Authors:  S Pace; A Longo; S Toon; P Rolan; A M Evans
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

6.  Carnitine deficiency and oxidative stress provoke cardiotoxicity in an ifosfamide-induced Fanconi Syndrome rat model.

Authors:  Mohamed M Sayed-Ahmed; Amal Q Darweesh; Amal J Fatani
Journal:  Oxid Med Cell Longev       Date:  2010 Jul-Aug       Impact factor: 6.543

7.  Role of carnitine in cancer chemotherapy-induced multiple organ toxicity.

Authors:  Mohamed M Sayed-Ahmed
Journal:  Saudi Pharm J       Date:  2010-08-05       Impact factor: 4.330

8.  A placebo-controlled trial of acetyl-L-carnitine and α-lipoic acid in the treatment of bipolar depression.

Authors:  Brian P Brennan; John Eric Jensen; James I Hudson; Caitlin E Coit; Ashley Beaulieu; Harrison G Pope; Perry F Renshaw; Bruce M Cohen
Journal:  J Clin Psychopharmacol       Date:  2013-10       Impact factor: 3.153

Review 9.  Pharmacokinetics of L-carnitine.

Authors:  Allan M Evans; Gianfranco Fornasini
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Isobutyrylcarnitine as a Biomarker of OCT1 Activity and Interspecies Differences in its Membrane Transport.

Authors:  Ole Jensen; Johannes Matthaei; Henry G Klemp; Marleen J Meyer; Jürgen Brockmöller; Mladen V Tzvetkov
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.